Our data suggest that therapeutic targeting of immune cell recruitment via the CXCL9– CXCL10–CXCL11/CXCR3 axis may be a valuable therapeutic strategy for resolution of inflammation in severe COVID-19, where it has become uncoupled from viral clearance. This evidence concerns the gene CXCL10 and COVID-19.